by The global Drug Eluting Balloon Market is estimated to be valued at US$ 616.6 million in 2022 and is expected to exhibit a CAGR of 8.3% over the forecast period of 2022-2030.
The Drug Eluting Balloon (DEB) market is witnessing significant growth due to the increasing prevalence of cardiovascular diseases, which has led to a rise in the demand for effective treatment options. DEBs are widely used in the treatment of various coronary and peripheral artery diseases. These balloons are coated with an anti-restenotic drug that is released into the artery during the inflation process, inhibiting restenosis or narrowing of the blood vessel.
However, the market faces challenges related to stringent regulatory requirements and the high cost associated with drug-eluting balloon procedures. These factors are expected to hinder market growth to some extent.
Market Key Trends:
One key trend in the Drug Eluting Balloon Market is the increasing preference for minimally invasive procedures. DEB catheterization procedures offer several advantages over traditional angioplasty, such as reduced risk of adverse events, shorter hospital stays, and quicker recovery times. This trend is driven by advancements in medical technology and growing patient awareness about the benefits of minimally invasive procedures.
For example, Medtronic, one of the key players in the market, offers IN.PACT Admiral drug-eluting balloons for the treatment of peripheral artery disease. These balloons have shown promising results in clinical studies and are increasingly being adopted by healthcare professionals worldwide.
Segment Analysis:
The Drug Eluting Balloon market is segmented based on the type of application. The coronary artery segment is dominating the market owing to the high prevalence of coronary artery diseases globally. According to the World Health Organization, cardiovascular diseases are the leading cause of death worldwide, accounting for over 17 million deaths annually. Drug eluting balloons are widely used in coronary interventions to prevent restenosis and improve patient outcomes.
Key Takeaways:
In terms of market size, the Drug Eluting Balloon market is expected to witness high growth, exhibiting a CAGR of 8.3% over the forecast period. This growth is primarily driven by increasing awareness and adoption of minimally invasive procedures for the treatment of cardiovascular diseases.
Regionally, North America is the fastest-growing and dominating region in the Drug Eluting Balloon market. The region has a well-established healthcare infrastructure, favorable reimbursement policies, and a large patient population with cardiovascular diseases. Moreover, key players such as Medtronic and Boston Scientific Corporation are headquartered in the region, contributing to its dominance in the market.
Key players operating in the global Drug Eluting Balloon market include Medtronic, Becton Dickinson and Company (BD), Boston Scientific Corporation, Cook Medical, B. Braun Melsungen AG, Koninklijke Philips N.V., Opto Circuits (India) Limited, Terumo Corporation, Surmodics, Inc., and Biotronik. These players focus on product innovation, strategic collaborations, and mergers and acquisitions to strengthen their market presence.
the Drug Eluting Balloon market is witnessing significant growth due to the increasing prevalence of cardiovascular diseases and the rising adoption of minimally invasive procedures. The market is dominated by Medtronic in the coronary artery segment. North America is the fastest-growing region in the market, driven by its well-established healthcare infrastructure and the presence of key players. The future of the Drug Eluting Balloon market looks promising with continued advancements in technology and increasing investments in research and development.
